PMC:7696151 / 104568-104883 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"4027","span":{"begin":286,"end":289},"obj":"Gene"},{"id":"4045","span":{"begin":88,"end":96},"obj":"Species"},{"id":"4116","span":{"begin":98,"end":101},"obj":"Chemical"},{"id":"4117","span":{"begin":113,"end":124},"obj":"Chemical"},{"id":"4118","span":{"begin":136,"end":146},"obj":"Chemical"},{"id":"4167","span":{"begin":73,"end":87},"obj":"Disease"}],"attributes":[{"id":"A4027","pred":"tao:has_database_id","subj":"4027","obj":"Gene:920"},{"id":"A4045","pred":"tao:has_database_id","subj":"4045","obj":"Tax:9606"},{"id":"A4116","pred":"tao:has_database_id","subj":"4116","obj":"MESH:D006886"},{"id":"A4117","pred":"tao:has_database_id","subj":"4117","obj":"MESH:D006918"},{"id":"A4118","pred":"tao:has_database_id","subj":"4118","obj":"MESH:D016049"},{"id":"A4167","pred":"tao:has_database_id","subj":"4167","obj":"MESH:D015658"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Paton, et al. (2002) [19] non-comparative clinical study22 asymptomatic HIV-1 infected patients HCQ (200 mg) + hydroxyurea (500 mg) + didanosine (125–200 mg), taken twice daily.48 weeks In the 12th week there was a significant reduction of 1.3 log10 in viral load and an increase in CD4+ percentage by mean 4.3%."}

{"project":"LitCovid-sentences","denotations":[{"id":"T713","span":{"begin":0,"end":315},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Paton, et al. (2002) [19] non-comparative clinical study22 asymptomatic HIV-1 infected patients HCQ (200 mg) + hydroxyurea (500 mg) + didanosine (125–200 mg), taken twice daily.48 weeks In the 12th week there was a significant reduction of 1.3 log10 in viral load and an increase in CD4+ percentage by mean 4.3%."}